Antithrombin Activity (ATIII), also known as AT III or AT 3, is a key biomarker that measures how effectively antithrombin, a natural anticoagulant protein, functions in the blood. Antithrombin is crucial for regulating clot formation by inhibiting thrombin and clotting factors like factor Xa, helping maintain a balance between clotting and bleeding. Normal ATIII activity ranges from 80% to 120%.
A decrease in ATIII activity may indicate inherited or acquired deficiencies and is often linked to conditions like deep vein thrombosis (DVT), pulmonary embolism, liver disease, nephrotic syndrome, disseminated intravascular coagulation (DIC), or vitamin K deficiency. While elevated ATIII activity is less common, it may occur during inflammation, certain stages of pregnancy, or after antithrombin supplementation or anticoagulant therapy.
Testing for antithrombin activity is vital for diagnosing clotting disorders, monitoring anticoagulant therapies (e.g., heparin), and evaluating overall hemostatic function. It is often performed alongside other tests, such as Protein C and S Activity, aPTT, PT/INR, and Factor V Leiden, to assess thrombophilia risk comprehensively. The test involves a blood draw, with plasma used as the specimen.
Emerging research highlights that certain demographic factors, such as Hispanic ethnicity, may influence ATIII activity in clinical contexts. This underscores the importance of considering patient-specific characteristics when interpreting test results.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.